CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancerLindsay W. Brubaker, Benjamin G. Bitler|Oncogenesis|2018Cited by 86
Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 ExpressionLyndsey S. Crump, Benjamin G. Bitler|Cancer Research Communications|2024Cited by 21
Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian CarcinomaBrooke E. Sanders, Benjamin G. Bitler|Molecular Cancer Therapeutics|2022Cited by 21
Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP InhibitorsTomomi M. Yamamoto, Benjamin G. Bitler|Molecular Cancer Therapeutics|2022Cited by 17
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune ActivationLily L. Nguyen, Benjamin G. Bitler|Molecular Cancer Therapeutics|2024Cited by 11